The combination OTX015/rituximab appeared more active in ABC-DLBCL cell lines [407], which was explained by the common targeting of the IL10 and STAT3 pathway by both OTX015 and rituximab [165, 407]. The gene discussed is IL10; the disease is diffuse large B-cell lymphoma.